Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion
Sponsors
Karolinska University Hospital, Ziekenhuis Aan De Stroom, F. Hoffmann-La Roche AG, AstraZeneca AB, Gilead Sciences Inc.
Conditions
Advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)Locally Advanced or Metastatic Unresectable Urothelial CancerMetastatic Castration Resistant Prostate Cancer (mCRPC)Metastatic non-small cell lung cancer (NSCLC)Non-metastatic HER2-positive Breast CancerProstate cancer
Phase 1
Phase 2
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE
RecruitingCTIS2022-501504-95-00
Start: 2023-06-23Target: 402Updated: 2025-08-18
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial
RecruitingCTIS2022-501551-90-00
Start: 2023-12-13Target: 583Updated: 2026-01-23
Phase 3
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Active, not recruitingCTIS2023-504996-26-00
Start: 2022-07-21Target: 424Updated: 2025-11-25
Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer
CompletedCTIS2024-513870-23-00
Start: 2021-06-28End: 2025-05-21Target: 391Updated: 2025-05-13
GCO-003 TARLANEC A randomized phase III trial study comparing tarlatamab with standard of care chemotherapy in patients with pre-treated advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas
Not yet recruitingCTIS2024-515948-23-00
Target: 129Updated: 2025-09-02